IC&RC ADC study materials
IC&RC ADC study resources

IC&RC ADC (IC&RC Addiction Professional Exams): Buprenorphine, Benzodiazepines, Pain, and Transportation Barriers

IC&RC ADC · Put your knowledge to work in context.

All case studies

Buprenorphine, Benzodiazepines, Pain, and Transportation Barriers

Lena, 52, has opioid use disorder and chronic low back pain. She has taken buprenorphine 16 mg daily for 14 months at a clinic 40 miles away. Her psychiatrist prescribes alprazolam 1 mg twice daily for anxiety. She has no car, and the bus runs to the clinic only twice weekly. She missed her last two counseling sessions, and her buprenorphine refill is due in three days. She rates her pain 8/10 and asks whether she can get 'something stronger.' Her urine last month was positive for benzodiazepines and negative for opioids. She lives alone; her 22-year-old son checks on her weekly. She reports no withdrawal but sometimes takes extra buprenorphine on bad pain days. She says she wants to stay off heroin and keep her housing. She has Medicaid and a case manager at the clinic.

1. What immediate safety and coordination concerns do you prioritize, and what actions do you take?

Read the worked answer

The combination of buprenorphine and alprazolam carries respiratory-depression risk, especially with extra buprenorphine doses; this is a safety concern, not a reason to discharge her. I would assess sedation, falls, breathing, overdose history, and whether she has naloxone. I would not tell her to stop either medication abruptly. With written releases, I would contact the buprenorphine prescriber and psychiatrist the same day to coordinate, clarify the negative opioid screen, and discuss a taper plan for alprazolam if appropriate. I would review her extra dosing and provide overdose prevention education. I would also address the missed counseling and refill timing to prevent interruption. ASAM dimensions guide level of care: her transportation barrier and co-occurring anxiety suggest need for coordinated outpatient or intensive outpatient services and case management. Documentation should show the risk assessment and coordination attempts.

2. Write at least two measurable treatment plan goals and explain how you would address her transportation barrier.

Read the worked answer

Goals should be SMART. Example one: Lena will attend at least two scheduled counseling sessions per week for the next four weeks, with attendance tracked in the EHR. Example two: Lena will report no extra buprenorphine doses for 30 days and will document any cravings or pain spikes on a daily log. Example three: Lena will have a scheduled appointment with her prescriber within seven days to review the buprenorphine and alprazolam regimen. Transportation is a concrete barrier: I would arrange telehealth for counseling if allowed, bus vouchers, the Medicaid transportation benefit, a warm handoff to the clinic case manager, and consolidated appointments. I would also explore a closer pharmacy and mail-order if appropriate. The plan should be developed with Lena, not for her, and reviewed for feasibility. If she misses again, the response is re-engagement, not automatic discharge.

3. How do you respond to her request for 'something stronger' for pain without splitting the treatment team?

Read the worked answer

I would validate that her pain is real and that 8/10 is exhausting, then be clear about my role: I do not prescribe and will not promise a medication change. I would ask what she hopes 'stronger' would do and what she has tried. I would assess for opioid craving, loss of control, and whether the request reflects inadequately treated pain, anxiety, or incipient relapse. With her consent, I would route the request to the prescriber and psychiatrist and document it. I would avoid criticizing the psychiatrist or buprenorphine, since splitting is a risk. I would offer nonpharmacologic support and pain coping skills, and coordinate a single message: the team will review the regimen together. If she is requesting a specific opioid, I would explore that directly and reinforce that buprenorphine is her agonist therapy. The response should be transparent, consistent, and documented.